Sign in

    Yan [ph]

    Vice President and Equity Research Analyst at Wells Fargo

    Yan [ph] is a Vice President and Equity Research Analyst at Wells Fargo Securities, specializing in the coverage of the Pharmaceuticals and Biotechnology sectors. He provides in-depth analysis and investment recommendations for leading companies such as Amgen, Biogen, Gilead Sciences, and Regeneron Pharmaceuticals, with a track record of accuracy reflected in a success rate above 60% and notable outperformance over sector averages as tracked by industry platforms. Yan began his career as a healthcare analyst with prior roles at J.P. Morgan and Barclays before joining Wells Fargo in 2018, consistently earning positive recognition for his detailed industry insights and client-oriented research. He is registered with FINRA and holds the Series 7, 63, and 86/87 licenses, underscoring his professional expertise and credentials in the financial sector.

    Yan [ph]'s questions to Kezar Life Sciences (KZR) leadership

    Yan [ph]'s questions to Kezar Life Sciences (KZR) leadership • Q2 2020

    Question

    Yan of Wells Fargo asked about the mechanism behind the UPCR reduction seen in the MISSION study, changes to the trial's enrollment criteria and potential label implications, and the enrollment status of the now-discontinued MARINA study.

    Answer

    President & CSO Christopher Kirk detailed that KZR-616 showed reductions in pathogenic autoantibodies and inflammatory gene modules, suggesting a broad immunomodulatory effect. Chief Medical Officer Noreen Henig added that the amended MISSION criteria are more reflective of real-world practice, which could support a broader label. She reiterated that no patients were ever enrolled in the MARINA study due to its overly restrictive protocol.

    Ask Fintool Equity Research AI